Company Search:
Advanced Search
Sponsored Links
Genmab A/S - ADR Company Snapshot
Genmab A/S operates in the Commercial physical research sector. In addition to historical fundamental analyses, the complete report available to purchase compares Genmab A/S with three other companies in this sector in the United States: Exact Sciences Corporation (2018 sales of $454.46 million of which 100% was License fees), Luminex Corporation ($315.82 million of which 100% was Technology, Strategic Partnerships & Ass), and Galapagos NV ($374.50 million of which 88% was R&D).

Sales Analysis. Genmab A/S reported sales of $478.18 million for the year ending December of 2018. This represents an increase of 32.0% versus 2017, when the company's sales were $362.24 million. Sales at Genmab A/S have increased during each of the previous five years (and since 2013, sales have increased a total of 304%).
  Stock Performance Chart for Genmab A/S - ADR
  Stock Data: Recent Stock Performance:
  Current Price (2/14/2020): 23.88
(Figures in U.S. Dollars)
1 Week -1.0%   13 Weeks 5.0%  
4 Weeks 6.9%   52 Weeks 55.4%  
Genmab A/S - ADR Key Data:
  Ticker: GMAB Country: United States
  Exchanges: OTC Major Industry: Commercial Services & Supplies
    Sub Industry: Commercial Physical Research
  2018 Sales 478,183,406
(Year Ending Jan 2019).
Employees: 377
  Currency: U.S. Dollars Market Cap: 15,480,337,280
  Fiscal Yr Ends: December Shares Outstanding: 648,255,330
  Share Type: Common Closely Held Shares:
Feedback | Terms and Conditions | Privacy Policy | Site Index
CorporateInformation® website and selected data Copyright © 2000 - by The Winthrop Corporation. All Rights Reserved. Except for quotations by established news media, no pages on this site may be reproduced, stored in a retrieval system, or transmitted for commercial purposes, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior written permission. Information is believed reliable, but accuracy, completeness and opinions are not guaranteed.